跳轉至內容
Merck
全部照片(1)

重要文件

SML3621

Sigma-Aldrich

Erlotinib

≥98% (HPLC)

同義詞:

4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline, 6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]- (3-ethynyl-phenyl)amine, Erlotinib free base, N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, NSC 718781, OSI-774

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C22H23N3O4
CAS號碼:
分子量::
393.44
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
暫時無法取得訂價和供貨情況

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

-10 to -25°C

SMILES 字串

N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI 密鑰

AAKJLRGGTJKAMG-UHFFFAOYSA-N

生化/生理作用

Erlotinib is an orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib binds to the ATP binding site of the receptor. It is used to treat lung and pancreatic cancer.
orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Jennifer Stamos et al.
The Journal of biological chemistry, 277(48), 46265-46272 (2002-08-28)
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-A resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical
Xiaoping He et al.
Scientific reports, 12(1), 8007-8007 (2022-05-15)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC. The therapeutic duration of lenvatinib is limited by resistance, but the underlying mechanism is unclear. To establish lenvatinib-resistant cells
Chike Osude et al.
Cells, 11(10) (2022-05-29)
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2). We investigated the mechanisms of EGFR-TKI

Questions

  1. Is this soluble in water?

    1 answer
    1. The solubility of this product in water is not determined. However, various sources state that is it poorly soluble in water.

      Helpful?

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務